NeueHealth — Q1 2024 Earnings Presentation
11 slides from NeueHealth's earnings presentation, May 8, 2024
Slide 1: NeueHealth First Quarter 2024 Earnings Presentation
NeueHealth First Quarter 2024 - Earnings Presentation May 8, 2024 Privileged & Confidential | © 2024
Slide 2: Disclaimer
Disclaimer Statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future re
Slide 3: NeueHealth: A Value-Driven Healthcare Company
NeueHealth: A Value-Driven Healthcare Company A value-driven, consumer-centric care model grounded in strong, ongoing relationships with provider and payor partners and proactive consumer engagement NeueHealth Value-driven care delivery and provider enablement business partnering with leading health
Slide 4: Overview of Q1 2024 Results for Continuing Operations
Overview of Q1 2024 Results for Continuing Operations Strong Results Through Q1 Position NeueHealth for Continued Success in 2024 Enterprise Metrics ($M) Revenue Gross Margin Adj. Operating Cost Ratio(1) Adjusted EBITDA(2) Key Considerations • Q1 ‘24 Revenue of $245.1 million slightly below expectat
Slide 5: Balance Sheet and Liquidity Highlights
Balance Sheet and Liquidity Highlights Focused on building a strong foundation for long-term sustainable growth Summary Balance Sheet Q1’24 Key Considerations March 31 March 31 • $256.4 million in total cash and investments, including $143.7 million ($ in thousands) 2024 2023 in regulated entities.
Slide 6: NeueHealth 2024 Outlook
NeueHealth 2024 Outlook NeueHealth • Revenue of ~$1 Billion • Adjusted Operating Cost Ratio 15% - 16%, excluding corporate costs. Including corporate costs this is expected to be 19% - 20%(1)(2) • Adjusted EBITDA between $15 million and $25 million(1) NeueCare NeueSolutions • 330,000 to 345,000 Year
Slide 7: Appendix
Appendix
Slide 8: Non-GAAP Reconciliation: Adjusted EBITDA
Non-GAAP Reconciliation: Adjusted EBITDA Three Months Ended March 31, March 31, ($ in thousands) 2024 2023 Net Loss ($4,177) ($169,461) Loss from discontinued operations 9,865 115,543 EBITDA adjustments from continuing operations Interest expense 2,930 7,787 Income tax (benefit) expense 663 1,259 De
Slide 9: Non-GAAP Reconciliation: Adjusted Operating Cost Ratio
Non-GAAP Reconciliation: Adjusted Operating Cost Ratio Three Months Ended March 31, March 31, ($ in thousands) 2024 2023 GAAP Operating Cost Ratio 27.3% 26.5% Impact of Share-based compensation expense (7.6)% (11.1)% Adjusted Operating Cost Ratio 19.7% 15.4% 9
Slide 10: Forward-Looking Non-GAAP Measures
Forward-Looking Non-GAAP Measures This presentation contains Adjusted EBITDA and Adjusted Operating Cost Ratio, which are non-GAAP financial measures. These non-GAAP financial measures are additions, and not substitutes for or superior to the most directly comparable GAAP financial measures, Net Inc
Slide 11: Slide 11